Lung Cancer
Conditions
Interventions
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adult patients aged >=18 years old; 2. Pathologically confirmed stage IIIB/IV or recurrent NSCLC; 3. Had at least one radiologically measurable disease as assessed using Response Evaluation Criteria in Solid Tumours (RECIST, version 1.1); and they did not receive local treatment such as radiotherapy or interventional therapy for the target lesions during anlotinib treatment; 4. Treated with anlotinib, or anlotinib-containing regimens between 1 June 2018 and 12 December 2019; 5. Had done at least one tumor assessment after anlotinib admission;
Exclusion criteria
Exclusion criteria: 1. Other pathological type than NSCLC including small cell lung cancer ( including mixed with small cell and non-small cell lung cancer ); 2. Patients who were diagnosed with malignancies other than NSCLC within the previous five years (except those with negligible risk of a metastases or death and treated with curative intent, based on primary investigator discretion) were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;ORR;DCR;DOR; | — |
Countries
China
Contacts
Public ContactFen Wang
Peking University Shenzhen Hospital
Outcome results
None listed